Lucitanib (Delitinib) is in phase II clinical trials for the treatment of refractory FGF-aberrant metastatic breast cancer, advanced or metastatic non-small cell lung cancer, small cell lung cancer and other solid tumors.
The compound was originally developed by Advenchen Laboratories, licensed to EOS Pharmaceuticals (acquired by Clovis Oncology in 2013) (except China) in 2008. In 2012, EOS Pharmaceuticals licensed to Servier (except China, Japan and US). In 2013, Servier licensed to Shanghai Institute of Mater Medica, Chinese Academy of Sciences in China.
Update Date:2016-02-19
Update Date:2016-02-18